Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTL Artelo Biosciences	$10.09 -0.4%	$11.22	$4.92 ▼ $28.60	$7.14M	1.36	148,178 shs	13,093 shs
BMY Bristol Myers Squibb	$47.86 +0.0%	$47.23	$42.96 ▼ $63.33	$97.40B	0.36	13.07 million shs	9.41 million shs
GPH Graphite One	C$0.98 +3.2%	C$0.83	C$0.64 ▼ C$1.14	C$99.23M	1.02	89,857 shs	151,599 shs
OGN Organon & Co.	$9.39 +0.3%	$9.75	$8.01 ▼ $23.10	$2.43B	0.6	4.75 million shs	3.58 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTL Artelo Biosciences	-0.39%	+11.74%	-37.21%	+82.79%	+27.40%
BMY Bristol Myers Squibb	+0.09%	+5.62%	+2.99%	+2.34%	-1.13%
GPH Graphite One	+3.16%	+1.03%	+42.03%	+24.05%	+20.99%
OGN Organon & Co.	+0.49%	+3.08%	-1.98%	+4.00%	-53.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARTL Artelo Biosciences	3.007 of 5 stars	3.8	5.0	0.0	0.0	2.2	0.0	0.6
BMY Bristol Myers Squibb	4.7419 of 5 stars	2.1	5.0	4.2	4.0	2.9	2.5	1.3
GPH Graphite One	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	4.7415 of 5 stars	3.3	2.0	1.7	3.7	2.5	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTL Artelo Biosciences	3.60	Strong Buy	$24.00	137.86% Upside
BMY Bristol Myers Squibb	2.24	Hold	$56.38	17.78% Upside
GPH Graphite One	0.00	N/A	N/A	N/A
OGN Organon & Co.	2.50	Moderate Buy	$18.00	91.80% Upside

Current Analyst Ratings Breakdown

Latest ARTL, OGN, BMY, and GPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2025	BMY Bristol Myers Squibb	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/5/2025	BMY Bristol Myers Squibb	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$42.00
8/4/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
8/1/2025	BMY Bristol Myers Squibb	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$51.00 ➝ $47.00
7/31/2025	BMY Bristol Myers Squibb	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
7/10/2025	BMY Bristol Myers Squibb	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$36.00 ➝ $34.00
7/8/2025	ARTL Artelo Biosciences	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/8/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00
6/11/2025	ARTL Artelo Biosciences	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/6/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	$5.31 per share	N/A
BMY Bristol Myers Squibb	$48.30B	2.02	$5.89 per share	8.13	$8.59 per share	5.57
GPH Graphite One	N/A	N/A	C$0.01 per share	94.17	C$0.44 per share	N/A
OGN Organon & Co.	$6.40B	0.38	$4.94 per share	1.90	$2.82 per share	3.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTL Artelo Biosciences	-$9.83M	-$17.94	N/A	N/A	N/A	N/A	-320.09%	-205.83%	N/A
BMY Bristol Myers Squibb	-$8.95B	$2.48	19.30	7.86	2.45	10.58%	80.04%	14.69%	10/30/2025 (Estimated)
GPH Graphite One	-C$4.90M	-C$0.07	N/A	∞	N/A	N/A	-10.96%	-6.61%	N/A
OGN Organon & Co.	$864M	$2.69	3.49	2.51	0.98	11.15%	163.88%	6.99%	10/30/2025 (Estimated)

Latest ARTL, OGN, BMY, and GPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ARTL Artelo Biosciences	-$0.13	-$5.61	-$5.48	-$5.61	N/A	N/A
8/5/2025	Q2 2025	OGN Organon & Co.	$0.94	$1.00	+$0.06	$0.56	$1.55 billion	$1.59 billion
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.07	$1.46	+$0.39	$0.64	$11.32 billion	$12.27 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	N/A
BMY Bristol Myers Squibb	$2.48	5.18%	N/A	100.00%	17 Years
GPH Graphite One	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.85%	N/A	2.97%	N/A

Latest ARTL, OGN, BMY, and GPH Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/6/2025	OGN Organon & Co.	quarterly	$0.02	0.9%	8/15/2025	8/15/2025	9/11/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTL Artelo Biosciences	N/A	0.49	0.49
BMY Bristol Myers Squibb	2.54	1.21	1.11
GPH Graphite One	0.02	1.09	0.33
OGN Organon & Co.	11.98	1.65	1.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTL Artelo Biosciences	0.87%
BMY Bristol Myers Squibb	76.41%
GPH Graphite One	0.07%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
ARTL Artelo Biosciences	5.80%
BMY Bristol Myers Squibb	0.09%
GPH Graphite One	28.81%
OGN Organon & Co.	1.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTL Artelo Biosciences	5	700,000	663,000	Not Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
GPH Graphite One	20	101.25 million	N/A	Not Optionable
OGN Organon & Co.	4,000	259.97 million	254.87 million	Not Optionable

ARTL, OGN, BMY, and GPH Headlines

Recent News About These Companies

Public Sector Pension Investment Board Has $12.16 Million Position in Organon & Co. (NYSE:OGN)

August 14 at 5:37 AM | marketbeat.com

NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation

August 13 at 10:15 AM | prnewswire.com

Organon: Valuation Discount Offset By Structural Headwinds

August 12 at 3:05 PM | seekingalpha.com

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

August 12 at 10:01 AM | zacks.com

Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend

August 11, 2025 | finance.yahoo.com

OGN vs. HQY: Which Stock Is the Better Value Option?

August 8, 2025 | zacks.com

Organon & Co. (NYSE:OGN) Given Average Recommendation of "Moderate Buy" by Brokerages

August 8, 2025 | marketbeat.com

Organon & Co. to Issue Quarterly Dividend of $0.02 (NYSE:OGN)

August 7, 2025 | marketbeat.com

Organon & Co. (OGN) Reports Q2 2025 Results

August 7, 2025 | insidermonkey.com

Organon & Co. Earnings Call: Resilience Amid Challenges

August 7, 2025 | theglobeandmail.com

Organon & Co. (NYSE:OGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

August 7, 2025 | finance.yahoo.com

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)

August 6, 2025 | seekingalpha.com

Organon & Co. (OGN) Slashes 13.13% on Disappointing Earnings

August 6, 2025 | msn.com

Organon & Co. (NYSE:OGN) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS

August 6, 2025 | marketbeat.com

Organon & Co. (NYSE:OGN) Trading Down 9.4% - Here's Why

August 6, 2025 | marketbeat.com

Organon Q2 2025 slides: Revenue guidance raised amid Women's Health strength

August 6, 2025 | kalkinemedia.comK

Organon (OGN) Fiscal Q2 Revenue Beats 1%

August 6, 2025 | fool.com

Organon & Co. Reports Q2 2025 Financial Results

August 6, 2025 | tipranks.com

Organon & Co. (OGN) Q2 2025 Earnings Call Transcript

August 5, 2025 | seekingalpha.com

Organon & Co. 2025 Q2 - Results - Earnings Call Presentation

August 5, 2025 | seekingalpha.com

Organon (OGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

August 5, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL, OGN, BMY, and GPH Company Descriptions

Artelo Biosciences NASDAQ:ARTL

$10.09 -0.04 (-0.39%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$10.40 +0.31 (+3.02%)

As of 08/14/2025 06:32 PM Eastern

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Bristol Myers Squibb NYSE:BMY

$47.86 +0.01 (+0.03%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$47.86 -0.01 (-0.02%)

As of 08/14/2025 07:53 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Graphite One CVE:GPH

C$0.98 +0.03 (+3.16%)

As of 08/14/2025 03:32 PM Eastern

Graphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Organon & Co. NYSE:OGN

$9.38 +0.03 (+0.27%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$9.39 +0.01 (+0.05%)

As of 08/14/2025 07:24 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time